These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37650302)

  • 1. Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation.
    Nguyen H; Nguyen HL; Lan PD; Thai NQ; Sikora M; Li MS
    Chem Soc Rev; 2023 Sep; 52(18):6497-6553. PubMed ID: 37650302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
    Jafary F; Jafari S; Ganjalikhany MR
    Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
    Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
    mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
    Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
    PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
    Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
    ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
    Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
    Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.